TrialBreast cancer research : BCR2026

Outcomes of Hormone receptor-positive/HER2-negative early breast cancer patients by risk of recurrence groups focusing on the intermediate-risk group: Retrospective analysis from GEICAM studies.

Sonia Servitja et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.